In this article, we review the current use of and future direction for genetic testing and tumor profiling in patients with metastatic castration-resistant prostate cancer.
Bryden Considine, DO
Advertisement
Articles by Bryden Considine, DO
Here, we review the current use and future direction of novel therapeutic targets in the treatment of castration-resistant prostate cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer
2
What is The State of Radiation Oncology in Head and Neck Cancers?
3
Elranatamab Significantly Improves PFS in R/R Multiple Myeloma Trial
4
Combining a PCNA Inhibitor with KRAS-Targeting Agents in PDAC
5